Sanofi builds focus on rare blood disorders and cancers

SanofiSome of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research as scientists look for new treatments for serious and life-threatening conditions. To help meet this need, Sanofi has significantly increased its focus on hematology, making a number of important investments to advance new therapies and improve the care of people affected by multiple myeloma, hemophilia, acquired thrombotic thrombocytopenic purpura (aTTP), cold agglutinin disease and other rare blood disorders. The company’s progress will be evident at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 1 - 4 in San Diego, CA.

"Hematology has become a major focus for Sanofi, and we are very excited about the progress we are making in advancing research on a relatively broad range of potential new treatments for people with rare blood disorders and blood cancers," said Bill Sibold, Executive Vice President and Head of Sanofi Genzyme, the specialty care global business unit of Sanofi. "We look forward to sharing that progress with the hematology community at this year’s ASH meeting."

Advancements in Cancer (Hematological Malignancies)

Data presented at ASH include the latest research regarding isatuximab, an anti-CD38 monoclonal antibody in late-stage development for patients with multiple myeloma, a rare plasma cell malignancy with high unmet medical need. Isatuximab is currently being investigated in four Phase 3 clinical trials, including three company sponsored pivotal trials.

Multiple Myeloma Oral Presentations at ASH:

  • Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (abstract 155; oral presentation on Saturday, December 1, 2018: 12:00-1:30 PM (PT))
  • Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant (abstract 595; oral presentation on Monday, December 3, 2018: 7:00-8:30 AM (PT))

Advancements in Rare Blood Disorders

Sanofi’s increased commitment to the rare blood disorders community follows the acquisition of two companies, Bioverativ and Ablynx, earlier this year. Sanofi will create a Rare Blood Disorders franchise in early 2019 that will become part of Sanofi Genzyme. In addition to two marketed therapies for the treatment of hemophilia, Sanofi’s pipeline includes novel investigational therapies in hemophilia, sickle cell disease(1), cold agglutinin disease and aTTP, a rare blood-clotting disorder.

Key Hemophilia Presentations at ASH:

  • BIVV001: The First Investigational Factor VIII Therapy to Break Through the VWF Ceiling in Hemophilia A, with Potential for Extended Protection for One Week or Longer (abstract 636; oral presentation on Monday, December 3, 2018: 10:30 AM-12:00 PM (PT)) (2)
  • ASPIRE Final Results Confirm Established Safety and Sustained Efficacy for Up to 4 Years of Treatment With rFVIIIFc in Previously Treated Subjects With Severe Hemophilia A (abstract 1192; poster on Saturday, December 1, 2018: 6:15-8:15 PM (PT)) (3)
  • B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B (abstract 1214; poster on Saturday, December 1, 2018: 6:15-8:15 PM (PT)) (3)

aTTP Oral Presentation at ASH:

  • Integrated Efficacy Results from the Phase II and Phase III Randomized Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura (abstract number 373; oral presentation on Sunday, December 2, 2018: 12:00-1:30 PM (PT))

Advancements in Rare Genetic Conditions

Sanofi Genzyme has worked in rare genetic conditions, including Gaucher disease for more than 30 years. Gaucher disease is an inherited genetic condition that can affect the blood, organs and bones. Because Gaucher disease has similar signs and symptoms of some more common hematologic malignancies, it is often misdiagnosed. Data presented at ASH includes oral eliglustat for the treatment of Gaucher disease type 1.

Gaucher Disease Presentations at ASH:

  • Long-Term Effects of Oral Eliglustat on Skeletal Manifestations of Gaucher Disease Type 1: Results from Four Completed Clinical Trials (abstract 2396; poster on Sunday, December 2, 6:00-8:00 PM (PT))
  • The Long-Term Adverse Event Profile of Oral Eliglustat for the Treatment of Gaucher Disease Type 1: Pooled Analysis of Data from 393 Patients in 4 Completed Trials (abstract 3692; poster on Monday, December 3, 6:00-8:00 PM (PT))

Isatuximab and BIVV001 are investigational agents and have not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency worldwide for the use under investigation.

The U.S. FDA has accepted for priority review the Biologics License Application for caplacizumab for treatment of patients 18 years of age and older experiencing an episode of aTTP. The European Commission approved caplacizumab as the first therapeutic specifically indicated for the treatment aTTP earlier this year.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

1. Bioverativ, a Sanofi company, and Sangamo Therapeutics, Inc. have an exclusive worldwide collaboration to develop and commercialize ZFN-mediated gene-edited cell therapies for the treatment of beta thalassemia and sickle cell disease.
2. Bioverativ, a Sanofi company, is responsible for the development of BIVV001
3. Bioverativ, a Sanofi company, and Sobi collaborate on the development and commercialization of rFVIIIFc and rFIXFc

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Breztri Aerosphere (PT010) approved in Japan for p…

AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

Human-on-a-chip model tests cancer drug efficacy a…

A reconfigurable "body-on-a-chip" model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organ...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Novartis successfully completes acquisition of Xii…

Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to trea...

LEO Pharma completes the acquisition of Bayer’s pr…

LEO Pharma and Bayer announced today the achievement of the relevant closing conditions to allow the transfer of Bayer’s global prescription dermatology business to LEO P...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

New study showing drug prolongs life for patients …

Women with ovarian cancer who have undergone four or more rounds of chemotherapy typically haven't had much hope that another treatment option will lengthen their lives i...

Pfizer completes acquisition of Therachon

Pfizer Inc. (NYSE: PFE) announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the ...